Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study

BACKGROUND: Apatinib, an oral small-molecule angiogenesis inhibitor, selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), which inhibits vascular endothelial growth factor (VEGF) stimulated endothelial cell migration and proliferation and decreases tumour growth and metastas...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Jianmiao, Gu, Weiguang, Jin, Jun, Zhang, Hua, Chen, Zecheng, Tang, Yicong, Zhang, Shunda, Yang, Shuang, Deng, Yanming, Feng, Weineng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745562/
https://www.ncbi.nlm.nih.gov/pubmed/33403012
http://dx.doi.org/10.1177/1758835920968472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745562/
https://www.ncbi.nlm.nih.gov/pubmed/33403012
http://dx.doi.org/10.1177/1758835920968472

Ejemplares similares